Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Medigus Ltd is a medical devices business based in the US. Medigus shares (MDGS) are listed on the NASDAQ and all prices are listed in US Dollars. Medigus employs 39 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $0.98 |
|---|---|
| 52-week range | $0.90 - $3.77 |
| 50-day moving average | $1.13 |
| 200-day moving average | $1.51 |
| Wall St. target price | N/A |
| PE ratio | 2.0457 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $0.48 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.9799 from 2022-01-25
| 1 week (2022-01-19) | -2.01% |
|---|---|
| 1 month (2021-12-23) | -5.78% |
| 3 months (2021-10-26) | -34.23% |
| 6 months (2021-07-26) | -43.68% |
| 1 year (2021-01-26) | -73.08% |
|---|---|
| 2 years (2020-01-24) | -47.60% |
| 3 years (2019-01-25) | 2.29 |
| 5 years (2017-01-26) | 84.85% |
Valuing Medigus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Medigus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Medigus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Medigus shares trade at around 2x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Revenue TTM | $2.9 million |
|---|---|
| Gross profit TTM | $-503,000 |
| Return on assets TTM | -14.18% |
| Return on equity TTM | 13.89% |
| Profit margin | 281.06% |
| Book value | $2.17 |
| Market capitalisation | $23.4 million |
TTM: trailing 12 months
We're not expecting Medigus to pay a dividend over the next 12 months.
Medigus's shares were split on a 1:4 basis on 15 July 2018. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Medigus shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Medigus shares which in turn could have impacted Medigus's share price.
Over the last 12 months, Medigus's shares have ranged in value from as little as $0.896 up to $3.77. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Medigus's is 2.077. This would suggest that Medigus's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Medigus Ltd. , a medical device company, develops, produces, and markets minimally invasive endo-surgical tools with direct visualization technology in the United States, the United Kingdom, Europe, Asia, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it develops, markets, and distributes software for internet users; develops and commercializes online and offline event planning software, as well as ticketing solutions; and operates online stores for the sale of various consumer products on the Amazon online marketplace. The company was incorporated in 1999 and is headquartered in Omer, Israel. .
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.